DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Local Triamcinolone Injection in Active Thyroid Orbitopathy

Information source: HaEmek Medical Center, Israel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Thyroid Disease

Intervention: Triamcinolone (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: HaEmek Medical Center, Israel

Official(s) and/or principal investigator(s):
Daniel Briscoe, MD, Study Chair, Affiliation: haemek medical center

Overall contact:
Daniel Briscoe, MD, Phone: 972-4-6494344, Email: daniel_br@clalit.org.il

Summary

Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.

Clinical Details

Official title: Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy .

Secondary outcome: To check if the level of TSH Receptor antibodies are affected by the local injection.

Detailed description: Local Steroid treatment may help in active thyroid orbitopathy. till today, systemic Steroids are the treatment for active thyroid orbitopathy which is associated with systemic adverse effects. In this study the investigators want to compare the effectiveness of local Triamcinolone therapy for active thyroid orbitopathy.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age>18 years.

- Active thyroid orbitopathy according to clinical activity score>=3.

Exclusion Criteria:

- Intraorbital or active infections.

- Tuberculosis.

- Other orbital disease.

- Pregnancy.

- Compressive optic neuropathy.

- Systemic steroid therapy within 6 months of study start.

Locations and Contacts

Daniel Briscoe, MD, Phone: 972-4-6494344, Email: daniel_br@clalit.org.il

Additional Information

Starting date: February 2011
Last updated: January 19, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017